Empowered Funds’s Ovid Therapeutics OVID Stock Holding History

Empowered Funds’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$203K	Buy	+91,234	New	+$163K	﹤0.01%	2019
2025 Q4	–	Sell	-91,234	Closed	-$119K	–	1642
2025 Q3	$119K	Hold	91,234	–	–	﹤0.01%	1782
2025 Q2	$30.1K	Hold	91,234	–	–	﹤0.01%	1742
2025 Q1	$28.5K	Sell	91,234 -47,181	-34%	-$29K	﹤0.01%	1609
2024 Q4	$129K	Sell	138,415 -6,925	-5%	-$7.75K	﹤0.01%	1558
2024 Q3	$172K	Buy	145,340 +7,370	+5%	+$7.7K	﹤0.01%	1340
2024 Q2	$106K	Buy	137,970 +9,900	+8%	+$27.6K	﹤0.01%	1340
2024 Q1	$391K	Buy	128,070 +9,625	+8%	+$32.2K	0.01%	1134
2023 Q4	$381K	Buy	118,445 +10,645	+10%	+$36.4K	0.01%	1048
2023 Q3	$414K	Buy	107,800 +8,848	+9%	+$31.8K	0.01%	973
2023 Q2	$325K	Buy	+98,952	New	+$336K	0.01%	936

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Empowered Funds's OVID Position: Q1 2026 in Review

Empowered Funds opened a new position in Ovid Therapeutics (OVID) in Q1 2026: 91,234 shares worth $203K. The stake represents ﹤0.01% of the portfolio and ranks #2019 among its holdings. This is a return to the name: Empowered Funds previously reported a position in OVID as recently as Q3 2025.

Empowered Funds first reported a position in OVID in Q2 2023 and has held it in 11 quarters since. The position peaked at $414K in Q3 2023. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

Empowered Funds held 91,234 shares of Ovid Therapeutics worth $203K as of Q1 2026.
Ovid Therapeutics was a new Empowered Funds position in Q1 2026.
Ovid Therapeutics made up ﹤0.01% of Empowered Funds's portfolio in Q1 2026, its #2019 holding.
Empowered Funds first reported a position in Ovid Therapeutics in Q2 2023 and has held it in 11 quarters since.
Empowered Funds's Ovid Therapeutics position peaked at $414K in Q3 2023.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Empowered Funds's 13F filing for Q1 2026, filed 15 May 2026.